Seelos Therapeutics Announces Closing of Public Offering of Common Stock
2020年2月14日 - 6:30AM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today the closing of its previously announced underwritten public
offering of 6,666,667 shares of its common stock, at a price to the
public of $0.75 per share. The net proceeds to Seelos from this
offering are expected to be approximately $4.3 million, after
deducting underwriting discounts and commissions and other
estimated offering expenses payable by Seelos. Seelos intends to
use the net proceeds from the offering for general corporate
purposes and to advance the development of its product candidates.
Raj Mehra, Ph.D., the President, Chief Executive Officer and
Chairman of the Board of Directors of Seelos, purchased $100,000 of
shares in the offering at the public offering price.
Benchmark Company acted as sole book-running manager for the
offering.
The securities described above were offered by Seelos pursuant
to a registration statement on Form S-1 (File No. 333-236002)
previously filed with the Securities and Exchange Commission (the
“SEC”) and declared effective by the SEC on February 10,
2020. This offering was made only by means of a prospectus
forming part of the effective registration statement. A final
prospectus relating to and describing the terms of the offering was
filed with the SEC and is available on the SEC’s website at
www.sec.gov. Copies of the final prospectus may also be obtained by
contacting The Benchmark Company, LLC, Attn: Prospectus Department,
150 E. 58th Street, 17th floor, New York, NY 10155, by calling
(212) 312-6700 or by e-mail at prospectus@benchmarkcompany.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
disorders. The Company’s robust portfolio includes several
late-stage clinical assets targeting psychiatric and movement
disorders, including orphan diseases. Seelos is based in New York,
New York. For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-Looking Statements:
This press release contains forward-looking statements related
to Seelos Therapeutics, Inc. and its subsidiaries under the safe
harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Forward-looking statements include statements
regarding the amount and anticipated use of proceeds from the
offering and other matters that are described in Seelos’ most
recent periodic reports filed with the SEC, including Seelos’
Annual Report on Form 10-K for the year ended December 31, 2018
filed on March 28, 2019, subsequent Quarterly Reports on Form 10-Q
and the final prospectus related to the public offering filed with
the SEC on February 11, 2020, including risks and uncertainties
associated with general economic and market conditions and the
other risk factors set forth in those filings. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release and
Seelos disclaims any intent or obligation to update these
forward-looking statements except as required by law.
Contact Information: Anthony Marciano Head of
Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 6 2024 まで 7 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 7 2023 まで 7 2024